SEC Form 4 · accession 0001123292-15-001302
IMMUNE DESIGN CORP. · IMDZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jan Henrik ter Meulen
Officer — Chief Scientific Officer
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 5:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $13.00 | Oct 30, 2015 | A | 40,000 | A | — | Oct 30, 2025 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Thirty-seven and a half percent (37.5%) of the shares underlying the option will vest on October 30, 2016, thirty-seven and a half percent (37.5%) of the shares underlying the option will vest on October 30, 2017, and the remainder of the shares underlying the option will vest on October 30, 2018.